INFLAMMATION NOT LDL

INFLAMMATION NOT LDL

At a medical conference I asked a Chairman of Medicine of a prestigious university how he would treat a man who had a massive heart attack with a cholesterol of only 140, LDL of 50 and no other risk factors.  He said ‘That’s a no brainer – give him a high dose statin.’  I then said, “That man’s cholesterol and LDL are excellent.  It’s probably only inflammation or a clot, so one could use vitamins and other nutrients instead.”  He abruptly and arrogantly said ‘No, give him a statin’ and he turned away.

LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.